In a report released today, Michael Matson from Needham reiterated a Buy rating on Zimmer Biomet Holdings (ZBH), with a price target of $192.00. The company’s shares closed last Friday at $159.91, close to its 52-week high of $165.93.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.4% and a 69.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Merit Medical Systems.
Zimmer Biomet Holdings has an analyst consensus of Strong Buy, with a price target consensus of $172.05, representing a 1.2% upside. In a report issued on January 25, BTIG also maintained a Buy rating on the stock with a $173.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $165.93 and a one-year low of $74.37. Currently, Zimmer Biomet Holdings has an average volume of 1.16M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.